首页>Diabetes research and clinical practice>Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes
Angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers for end-stage renal disease/mortality in type 2 diabetes
作者单位：University of New Mexico College of Pharmacy, Albuquerque, NM, United States[1]New Mexico VA Health Care System, Albuquerque, NM, United States, University of New Mexico School[2]VA Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, Albuquerque, NM[3]University of New Mexico College of Pharmacy, Albuquerque, NM, United States, Oxford Outcomes[4]
换一批
